Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

917 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT-X) determined by the Sysmex XE-2100™.
Le Roux G, Vlad A, Eclache V, Malanquin C, Collon JF, Gantier M, Schillinger F, Peltier JY, Savin B, Letestu R, Baran-Marszak F, Fenaux P, Ajchenbaum-Cymbalista F. Le Roux G, et al. Among authors: fenaux p. Int J Lab Hematol. 2010 Dec;32(6 Pt 1):e237-43. doi: 10.1111/j.1751-553X.2010.01247.x. Int J Lab Hematol. 2010. PMID: 20670338
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, Gardin C. Kelaidi C, et al. Among authors: fenaux p. Leuk Res. 2018 Aug;71:67-74. doi: 10.1016/j.leukres.2018.05.007. Epub 2018 May 29. Leuk Res. 2018. PMID: 30025278
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
Kelaidi C, Park S, Brechignac S, Mannone L, Vey N, Dombret H, Aljassem L, Stamatoullas A, Adès L, Giraudier S, de Botton S, Raynaud S, Lepelley P, Picard F, Leroux G, Daniel MT, Bouscary D, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies (GFM). Kelaidi C, et al. Among authors: fenaux p. Leuk Res. 2008 Jul;32(7):1049-53. doi: 10.1016/j.leukres.2007.11.037. Epub 2008 Jan 11. Leuk Res. 2008. PMID: 18191202
Myelodysplastic syndromes.
Fenaux P. Fenaux P. Hematol Cell Ther. 1996 Oct;38(5):363-80. doi: 10.1007/s00282-996-0363-7. Hematol Cell Ther. 1996. PMID: 8915667 Review.
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.
Itzykson R, Ayari S, Vassilief D, Berger E, Slama B, Vey N, Suarez F, Beyne-Rauzy O, Guerci A, Cheze S, Thomas X, Stamatoullas A, Gardembas M, Bauduer F, Kolb A, Chaury MC, Legros L, Damaj G, Chermat F, Dreyfus F, Fenaux P, Ades L; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: fenaux p. Leukemia. 2009 Apr;23(4):673-8. doi: 10.1038/leu.2008.362. Epub 2009 Jan 8. Leukemia. 2009. PMID: 19151787 Clinical Trial.
Epigenetics of myelodysplastic syndromes.
Itzykson R, Fenaux P. Itzykson R, et al. Among authors: fenaux p. Leukemia. 2014 Mar;28(3):497-506. doi: 10.1038/leu.2013.343. Epub 2013 Nov 19. Leukemia. 2014. PMID: 24247656 Review.
Is apoptosis a massive process in myelodysplastic syndromes?
Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P. Lepelley P, et al. Among authors: fenaux p. Br J Haematol. 1996 Nov;95(2):368-71. doi: 10.1046/j.1365-2141.1996.d01-1915.x. Br J Haematol. 1996. PMID: 8904894
Meeting report: myelodysplastic syndromes at ASH 2007.
Itzykson R, Gardin C, Fenaux P. Itzykson R, et al. Among authors: fenaux p. Leukemia. 2008 May;22(5):893-7. doi: 10.1038/leu.2008.45. Epub 2008 Mar 6. Leukemia. 2008. PMID: 18323798
917 results